Site & Patient Solutions case studies
See how we are supporting patients and sites for efficient clinical trial operations
Explore our library of case studies for patient centric clinical trial services.
An end-to-end solution providing the support and structure to efficiently operationalise clinical trials. Site & Patient Solutions offers faster study start-up, increased patient enrolment and retention, and site training and support to ensure compliance, quality data and inspection readiness.
More patients enrolled faster with fewer sites
Accellacare Site Network reduced the time and cost curve for a respiratory syncytial virus (RSV) vaccine study.
Reducing participant burden in VMS study
ICON supported a proof-of-concept real-world study for participants experiencing bothersome vasomotor symptoms (VMS). The hybrid decentralised clinical trial (DCT) model included both on-site and remote visits, enrolling approximately 1,000 participants across the United States.
Improving compliance in an Alzheimer’s disease DCT
ICON supported a pre-clinical Alzheimer’s disease study focused on biomarker and genetic testing, involving
600 participants across the United States. The trial was fully remote, led by two remote principal investigators
(PIs), and utilised a digital recruitment strategy.
600 participants across the United States. The trial was fully remote, led by two remote principal investigators
(PIs), and utilised a digital recruitment strategy.
Transitioning from a Phase 3 study to an EAP
This case study highlights the strategic execution of an Expanded Access Program (EAP) across multiple global regions, Europe, Asia-Pacific, and Latin America, following a Phase 3 clinical study.
Rapid deployment of a compassionate use program
During the peak of the COVID-19 pandemic, a global compassionate use program (CUP) was urgently needed to provide compassionate use of a promising treatment. The program required rapid deployment across multiple regions to support hospitalized patients.
Accelerating site activation by over 50%
A global biopharma sponsor partnered with ICON for a Phase 1/2 oncology study. ICON piloted a site-focused activation model with dedicated Site Partners, supported by centralized oversight and tech-enabled processes, to reduce site burden and accelerate timelines.
Accelerating study start-up through a unit-based, stand-alone model
A top 10 pharma company partnered with ICON to improve study start-up in the U.S., shifting from an FTE model to unit-based delivery. Using proprietary systems and centralized teams, ICON reduced cycle times and identified further efficiency opportunities.
Reducing the time and cost curve
A large pharmaceutical company was conducting a Phase 2 study for adults with obesity. They contracted 42 sites globally, including 6 Accellacare sites in the US to recruit for three cohorts and conduct the study.
Extensive patient access and recruitment strategies
A large pharmaceutical company was conducting a Phase 2 study for adults with a BMI of 18-32. They contracted 60 US sites, including 9 Accellacare sites to recruit for two cohorts and conduct the study.
Eliminating enrolment delays to bring an AI-enabled SaMD to market
A medical device developer faced clinical evaluation timeline delays due to under-enrolment. Discover how the collaborative partnership between the sponsor and ICON’s Medical Device & Diagnostics Research team steered the study from patient enrolment to FDA submission and approval.
Optimising site selection in a rescue study
A pharmaceutical sponsor launched a global trial for elderly UTI patients, opening 125 sites across 15 countries. Enrolment lagged at 1 patient per site per month, with 70% non-enrolling. ICON was brought in to rescue the study.
Accelerated auxiliary medicine procurement for MASH trial
A biotechnology company required vitamin D distribution as an auxiliary medication for a phase 3 MASH and fibrosis clinical study. When the original supplement vendor was unable to support the study’s full global scope, the company engaged ICON’s Accelerated Pharmaceutical Solutions (APS) team to step in on short notice.